Demo
VTGN Nasdaq· VistaGen Therapeutics Inc
FundamentalsNews digest Peer analysis
Login
VTGN Nasdaq· VistaGen Therapeutics Inc
Earnings report Q4 2023

VTGN Reports Increase in Revenue in Latest Quarter

Segments of revenue

In the latest quarter, VTGN reported total revenues of $411.4 thousand, compared to $179.6 thousand in the same quarter of the previous year. The revenue primarily consisted of sublicense and other revenue, which amounted to $411.4 thousand.

Strengths

VTGN demonstrated a significant increase in revenue compared to the same quarter of the previous year. This growth can be attributed to the increase in sublicense and other revenue. The management comments in the report did not provide specific details regarding the factors driving the increase in revenue.

Challenges

Despite the increase in revenue, VTGN still reported a loss from operations of $7.88 million in the latest quarter. This indicates that the company's operating expenses exceeded its revenue. The report highlights research and development expenses of $4.54 million and general and administrative expenses of $3.76 million as the main contributors to the operating expenses.

Noteworthy

The report does not mention any noteworthy events or developments that could impact VTGN's performance in the latest quarter.

Summary

VTGN reported a significant increase in revenue in the latest quarter, primarily driven by sublicense and other revenue. However, the company still faced challenges as its operating expenses exceeded its revenue, resulting in a loss from operations. The report did not provide specific details regarding the factors behind the increase in revenue.

Source documents

Form 10-Q  filed on Feb 13, 2024
73 pages scanned

Reference data

Company financials Q4 revenue 411.4k
Analyst estimates Q4 EPS missed by -20.00%
Sign up to Fey

Get in-depth analysis on thousands of stocks for just $30/month. Cancel anytime.